2025 — HBOT in Long COVID (4-arm RCT, n=101)
One-paragraph summary
Four-arm randomized placebo-controlled prospective double-blind trial of hyperbaric oxygen therapy in 101 long COVID patients. Arms: (A) 100% O₂ at 253 kPa / 2.5 ATA; (B) 40% O₂ at 253 kPa; (C) 100% O₂ at 101.3 kPa / 1 ATA; (D) 21% O₂ at 101.3 kPa. Groups B and C received similar effective oxygen dose (101.3 kPa) — clean placebo control. Outcomes: VAS quality-of-life, EQ-5D-5L, C19-YRSm, 6-minute walking test, 5 neurocognitive tests. For the project, this is a methodologically rigorous (4-arm, double-blind, placebo-controlled) test of HBOT in a PCC population that includes post-COVID-FM phenotypes — directly relevant to the cure-path framework via the post-COVID-FM cube cell. Adds RCT-level evidence to the otherwise case-report-heavy HBOT-FM literature.
Claims as triples
hyperbaric_oxygen_therapy — modulates → post_covid_syndrome[evidence: n=101 4-arm placebo-controlled RCT; confidence: emerging]hyperbaric_oxygen_therapy — bridges → fm_central_only[evidence: PCC includes post-COVID-FM phenotypes; confidence: bridging]hyperbaric_oxygen_therapy — modulates → mitochondrial_dysfunction[evidence: mechanism rationale — increased tissue oxygenation supports mitochondrial respiration; confidence: bridging]
Triangulation notes
- First methodologically rigorous HBOT trial in the project's evidence base (prior HBOT evidence was case-series-level).
- Connects to Hypothesis 1's mitochondrial-quality-control framework as a non-pharmacological intervention; complements pharmacological mitochondrial-protective agents (idebenone, creatine, metformin).
- Discovered via Probe 4 (HBOT in FM); scored ingestion-worthy; promoted in Recommendation 3.
Open questions raised
- Does HBOT efficacy correlate with HERV-W ENV positivity or with plasma cf-mtDNA / ISG signature?
- HBOT + temelimab combination for upstream + downstream loop interruption — feasibility?